Professor Zhisong He and Professor Xin Yao: New Approval of Toripalimab for Urothelial Carcinoma, Chinese Clinical Evidence Powers CSCO Guidelines and Reshapes the National Treatment Landscape
For nearly four decades, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma (UC). However, its limitations—including modest survival outcomes and significant treatment-related toxicity—have persisted as major clinical challenges.








